Relmada Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-57.4M | $-80.0M | $-98.8M | $-157.0M | $-125.8M | $-59.5M | $-15.0M | $-9.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | $1.3K | $3.8K | $4.4K | $2.6K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $13.9M | $30.2M | $43.8M | $44.2M | $40.5M | $20.8M | $3.2M | $518.0K |
| Net Cash from Operating Activities | $-45.8M | $-51.8M | $-51.7M | $-103.8M | $-91.9M | $-27.8M | $-12.1M | $-6.0M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | $182.1M | $84.8M | $12.4K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-48.1M | $51.6M | $50.5M | $19.7M | $-54.1M | $-34.4M | $-80.2M | $-12.4K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $93.6M | $-40.3K | $-98.5K | $45.0M | $187.9M | $28.5M | $126.1M | $6.5M |
| Net Change in Cash | — | — | — | — | — | — | $7.0M | $528.4K |
| Free Cash Flow | — | — | — | — | — | $-209.9M | $-96.9M | $-6.0M |